Figure 2From: Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada Validation of the model. Panel A shows the model predicted cervical cancer incidence per 100,000 women compared to reported data from Canada in 2007 [43]. Panel B shows the model predicted genital warts incidence compared to data reported by Marra et al. [44].Back to article page